Postpartum Depression Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Sage Therapeutics, Epharmix, Marinus Pharmaceuticals, Lipocine, Brii Biosciences

February 21 18:58 2024
Postpartum Depression Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Sage Therapeutics, Epharmix, Marinus Pharmaceuticals, Lipocine, Brii Biosciences
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, several major pharma and biotech companies are working on developing various pipeline drugs in the Postpartum Depression therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Postpartum Depression Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Postpartum Depression Market. 

The Postpartum Depression Pipeline report embraces in-depth commercial, regulatory, and Postpartum Depression clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Postpartum Depression drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Postpartum Depression Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Postpartum Depression treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Postpartum Depression therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Postpartum Depression companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Postpartum Depression drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Postpartum Depression therapeutic market.

Postpartum Depression Therapeutics Landscape

Several prominent companies are actively involved in developing therapies for Postpartum Depression. Among these key players, Sage Therapeutics stands out, along with others, for advancing their Postpartum Depression drug candidates to the mid to advanced stages of clinical trials, specifically Phase III. This significant progress underscores the dedication within the pharmaceutical industry to address the challenges posed by Postpartum Depression and emphasizes the commitment of Sage Therapeutics and other companies to advancing innovative treatments for individuals affected by this condition, aiming to improve maternal mental health outcomes.

Postpartum Depression Companies Actively Working in the Therapeutic Market Include:

  • Sage Therapeutics

  • Epharmix

  • Marinus Pharmaceuticals

  • Lipocine

  • Brii Biosciences

And Many Others

Emerging and Marketed Postpartum Depression Drugs Covered in the Report Include:

  • Zuranolone (Sage Therapeutics)

  • Ganaxolone (Marinus Pharmaceuticals)

  • LPCN 1154 (Lipocine), 

  • BRII-296 (Brii Biosciences)

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Postpartum Depression Companies Working in the Market:

Analysis of Emerging Postpartum Depression Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Postpartum Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous

  • Intravenous

  • Oral

Learn How the Postpartum Depression Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Postpartum Depression Treatment Patterns

4. Postpartum Depression – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Postpartum Depression Late Stage Products (Phase-III)

7. Postpartum Depression Mid-Stage Products (Phase-II)

8. Postpartum Depression Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Postpartum Depression Discontinued Products

13. Postpartum Depression Product Profiles

14. Major Postpartum Depression Companies in the Market

15. Key Products in the Postpartum Depression Therapeutics Segment

16. Dormant and Discontinued Products

17. Postpartum Depression Unmet Needs

18. Postpartum Depression Future Perspectives

19. Postpartum Depression Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Other Trending Healthcare Reports By DelveInsight

Decompensated Cirrhosis Market

“Decompensated Cirrhosis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Decompensated Cirrhosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Decompensated Cirrhosis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States